Stellar Biotech Inc (SBOTF) 0.9200 $SBOTF
Stellar Biotechnologies Reports Third Quarter 2014 Financial Results and Recent Corporate Developments
Marketwire - Thu Jul 10, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), a leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets, has reported financial results for the third quarter and nine months ended May 31, 2014, and provided operational highlights.
Stellar Biotechnologies Appoints Two Members to Scientific Advisory Board
Marketwire - Fri Jun 06, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today the appointment of Gregory T. Baxter, Ph.D. and Charles V. Olson, D.Sc. to the Company's Scientific Advisory Board (SAB). They will join Daniel C. Adelman, M.D., Malcolm Gefter, Ph.D., Daniel Morse, Ph.D. and Andrew Saxon, M.D. on the SAB. Stellar's SAB is composed of eminent scientists and physicians representing a range of disciplines including immunology, molecular biology and biochemistry. The SAB will be an ongoing resource to provide Stellar's management with counsel and guidance pertaining to the research, development, and clinical application of Stellar's KLH technology.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bfdsrl/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AIMM Therapeutics B.V. - Actelion Ltd - Adenium Biotech ApS - Akthelia pharmaceuticals - AmpliPhi Biosciences - AvidBiotics Corp. - Biota Pharmaceuticals - Cubist Pharmaceuticals - Daiichi Sankyo Company, - ImmunoBiology Ltd. - Immuron - Mapp Biopharmaceutical - MedImmune, LLC - Merck & Co. - Microbiotix - Micropharm Ltd - Morphochem AG - Novartis AG - Oragenics - Paratek Pharmaceuticals - Pfizer Inc. - Ranbaxy Laboratories - Ruthigen - Sorrento Therapeutics - Stellar Biotechnologies - Summit plc - Synthetic Biologics - The Medicines Company - Valneva SE - VaxInnate For more information visit http://www.researchandmarkets.com/research/bf...lostridium
Stellar Biotechnologies Presenting Today at 2014 TSX Venture 50(R) Spotlight Event
Marketwire - Tue Apr 01, 8:03AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced that the company is presenting today at the 2014 TSX Venture 50(R) Spotlight Event being held in Calgary, Canada.
Stellar Biotechnologies Presents Poster on KLH Achievements at Gordon Research Conference
Marketwire Canada - Mon Mar 03, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of a poster at the Gordon Research Conference (GRC) on Marine Natural Products, being held March 2-7, 2014 in Ventura, California.
Stellar Biotechnologies to Present at the 26th Annual ROTH Capital Growth Conference
Marketwire Canada - Thu Feb 27, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a company focused in the immunotherapy arena with world-leading technology in Keyhole Limpet Hemocyanin (KLH) protein, announced today that the Company will present at the 26th Annual ROTH Capital Partners Growth Conference to be held March 9-12, 2014 at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
Stellar Biotechnologies Reports on Annual General and Special Meeting
Marketwire - Tue Feb 18, 8:06AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announces that the Company held its Annual General and Special Meeting of Shareholders (the "Meeting" on Thursday, February 13, 2014 at which all Meeting resolutions were approved. The resolutions passed at the Meeting include the following:
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Stellar Biotechnologies Named 2014 TSX Venture 50(R) Company
Marketwire Canada - Thu Feb 13, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has been named to the 2014 TSX Venture 50(R), an exclusive ranking of the top performing companies on the TSX Venture Exchange.
Stellar Biotechnologies Presents KLH Verification Method at Aquaculture America Conference
Marketwire Canada - Wed Feb 12, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the presentation of a poster at Aquaculture America 2014 (Seattle, February 9-12, 2014), describing a new method for verifying authenticity of Keyhole Limpet Hemocyanin (KLH) product.
Mindoro Welcomes Significant New Investor as Prime Resources Holdings, Inc. Acquires 13.33% of Mindoro's Shares
Marketwire - Fri Jan 17, 7:01AM CST
Mindoro Resources Ltd. (TSX VENTURE: MIO)(ASX: MDO)(FRANKFURT:WKN 906167) ("Mindoro", or "the Company" is pleased to advise that Prime Resources Holdings, Inc. ("PRHI" has acquired approximately 13.33% of Mindoro's issued and outstanding common shares through a secondary trade in the market.
Stellar Biotechnologies, Inc. to Present at Two Investor Conferences in January
Marketwire - Mon Jan 06, 8:15AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company will present at two upcoming investor conferences in January: the Biotech Showcase 2014 in San Francisco and the Noble Financial Capital Markets Tenth Annual Equity Conference in South Florida.
Stellar Biotechnologies Issues Year-End Results and Highlights From 2013
Marketwire Canada - Thu Jan 02, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the filing of its annual report for the fiscal year ended August 31, 2013 and financial results and operational highlights for 2013.
Stellar Biotechnologies Reports Third Quarter 2014 Financial Results and Recent Corporate Developments
Marketwire - Thu Jul 10, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), a leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets, has reported financial results for the third quarter and nine months ended May 31, 2014, and provided operational highlights. Stellar Biotechnologies Appoints Two Members to Scientific Advisory Board
Marketwire - Fri Jun 06, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) announced today the appointment of Gregory T. Baxter, Ph.D. and Charles V. Olson, D.Sc. to the Company's Scientific Advisory Board (SAB). They will join Daniel C. Adelman, M.D., Malcolm Gefter, Ph.D., Daniel Morse, Ph.D. and Andrew Saxon, M.D. on the SAB. Stellar's SAB is composed of eminent scientists and physicians representing a range of disciplines including immunology, molecular biology and biochemistry. The SAB will be an ongoing resource to provide Stellar's management with counsel and guidance pertaining to the research, development, and clinical application of Stellar's KLH technology. Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bfdsrl/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AIMM Therapeutics B.V. - Actelion Ltd - Adenium Biotech ApS - Akthelia pharmaceuticals - AmpliPhi Biosciences - AvidBiotics Corp. - Biota Pharmaceuticals - Cubist Pharmaceuticals - Daiichi Sankyo Company, - ImmunoBiology Ltd. - Immuron - Mapp Biopharmaceutical - MedImmune, LLC - Merck & Co. - Microbiotix - Micropharm Ltd - Morphochem AG - Novartis AG - Oragenics - Paratek Pharmaceuticals - Pfizer Inc. - Ranbaxy Laboratories - Ruthigen - Sorrento Therapeutics - Stellar Biotechnologies - Summit plc - Synthetic Biologics - The Medicines Company - Valneva SE - VaxInnate For more information visit http://www.researchandmarkets.com/research/bf...lostridium
Stellar Biotechnologies Presenting Today at 2014 TSX Venture 50(R) Spotlight Event
Marketwire - Tue Apr 01, 8:03AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), announced that the company is presenting today at the 2014 TSX Venture 50(R) Spotlight Event being held in Calgary, Canada. Stellar Biotechnologies Presents Poster on KLH Achievements at Gordon Research Conference
Marketwire Canada - Mon Mar 03, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of a poster at the Gordon Research Conference (GRC) on Marine Natural Products, being held March 2-7, 2014 in Ventura, California. Stellar Biotechnologies to Present at the 26th Annual ROTH Capital Growth Conference
Marketwire Canada - Thu Feb 27, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), a company focused in the immunotherapy arena with world-leading technology in Keyhole Limpet Hemocyanin (KLH) protein, announced today that the Company will present at the 26th Annual ROTH Capital Partners Growth Conference to be held March 9-12, 2014 at The Ritz-Carlton, Laguna Niguel in Dana Point, California. Stellar Biotechnologies Reports on Annual General and Special Meeting
Marketwire - Tue Feb 18, 8:06AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), announces that the Company held its Annual General and Special Meeting of Shareholders (the "Meeting" on Thursday, February 13, 2014 at which all Meeting resolutions were approved. The resolutions passed at the Meeting include the following: Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Stellar Biotechnologies Named 2014 TSX Venture 50(R) Company
Marketwire Canada - Thu Feb 13, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has been named to the 2014 TSX Venture 50(R), an exclusive ranking of the top performing companies on the TSX Venture Exchange. Stellar Biotechnologies Presents KLH Verification Method at Aquaculture America Conference
Marketwire Canada - Wed Feb 12, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the presentation of a poster at Aquaculture America 2014 (Seattle, February 9-12, 2014), describing a new method for verifying authenticity of Keyhole Limpet Hemocyanin (KLH) product. Mindoro Welcomes Significant New Investor as Prime Resources Holdings, Inc. Acquires 13.33% of Mindoro's Shares
Marketwire - Fri Jan 17, 7:01AM CST
Mindoro Resources Ltd. (TSX VENTURE: MIO)(ASX: MDO)(FRANKFURT:WKN 906167) ("Mindoro", or "the Company"
is pleased to advise that Prime Resources Holdings, Inc. ("PRHI" has acquired approximately 13.33% of Mindoro's issued and outstanding common shares through a secondary trade in the market. Stellar Biotechnologies, Inc. to Present at Two Investor Conferences in January
Marketwire - Mon Jan 06, 8:15AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company will present at two upcoming investor conferences in January: the Biotech Showcase 2014 in San Francisco and the Noble Financial Capital Markets Tenth Annual Equity Conference in South Florida. Stellar Biotechnologies Issues Year-End Results and Highlights From 2013
Marketwire Canada - Thu Jan 02, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the filing of its annual report for the fiscal year ended August 31, 2013 and financial results and operational highlights for 2013. 
